drugset / Trial / NCT00560976
Serum NGAL Levels in Hemodialysis (HD) Patients; Relation to Iron Status, HD and Intravenous (IV) Iron Administration
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess changes in serum levels of the siderophore binding protein NGAL by hemodialysis without and with intravenous iron administration
Timeline
- Start
- 2005-12
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iron sucrose | Unknown | 100 mg | Intravenous |
| Subject | ferric gluconate | Unknown | 62.5 mg | Intravenous |